Treace Announces Participation at Stifel 2024 Healthcare Conference
Treace Announces Participation at Stifel 2024 Healthcare Conference
PONTE VEDRA, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty and Adductoplasty Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, beginning at approximately 8:00 am ET.
弗羅裏達州龐特維德拉，2024年11月18日 (環球新聞社) -- Treace Medical Concepts, Inc. ("Treace" 或 "公司") (NasdaqGS: TMCI)，一家醫療科技公司，通過其旗艦的Lapiplasty和Adductoplasty Procedures推動短趾外翻以及相關中足畸形的外科治療方式發生了根本性轉變，今天宣佈首席執行官約翰·特里斯和首席財務官馬克·L·黑爾將於2024年11月19日星期二參加Stifel 2024年醫療保健大會中的爐邊對話，預計在美國東部時間上午8點左右開始。
A live webcast and replay of the fireside chat will be available on the Company's investors relations website at
公司的投資者關係網站上將提供爐邊聊天的直播和回放，網址爲
Internet Posting of Information
Treace routinely posts information that may be important to investors in the "Investor Relations" section of its website at . The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
信息的網絡發佈
Treace定期在其網站的"投資者關係"部分發布可能對投資者重要的信息。 公司鼓勵投資者和潛在投資者定期查看Treace網站以獲取有關Treace的重要信息。
About Treace Medical Concepts
關於Treace Medical Concepts：Treace Medical Concepts， Inc.是一家醫療技術公司，旨在推進外科管理拇趾外翻及相關足弓畸形的護理標準。拇趾外翻是一種複雜的三維畸形，源於足部中部的不穩定關節，影響約6700萬美國人，其中Treace估計有110萬人需要每年手術治療。 Treace開創並取得了Lapiplasty 3D Bunion Correction System的專利--這是一種由儀器、植入物和外科方法組成的組合，旨在通過外科手術矯正拇趾畸形的三個平面，並固定不穩定的關節，解決拇趾畸形的根本原因，幫助病人恢復活力的生活方式。爲了進一步支持拇趾畸形患者的需求，Treace推出了Adductoplasty Midfoot Correction System，旨在重複性外科手術矯正足弓畸形，以及其Hammertoe PEEk Fixation System，旨在解決錘趾、雞爪趾和槌狀趾畸形。該公司通過推出SpeedPlate Rapid Compression Implants擴大了其足踝市場份額--這是一種具有廣泛適用性的創新固定平台，可應用於Lapiplasty和Adductoplasty手術，以及足部其他常見骨融合手術。有關更多信息，請訪問網站。
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty 3D Bunion Correction System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty and Adductoplasty procedures, as well as other common bone fusion procedures of the foot. For more information, please visit .
Treace Medical Concepts, Inc.是一家醫療科技公司，旨在推動提高拇囊腫及相關蹠足部畸形手術治療的標準。拇囊腫是源自腳部中部不穩定關節的複雜三維畸形，約影響6700萬美國人，其中Treace估計有110萬人每年適合手術。Treace率先並獲得專利的Lapiplasty 3D拇囊矯正系統，包括工具、植入物和手術方法的組合，旨在手術矯正拇囊畸形的三個平面，並固定不穩定關節，解決拇囊炎的根本原因，幫助患者重返活躍生活方式。爲進一步滿足拇囊腫患者的需求，Treace推出了其Adductoplasty中足矯正系統，旨在可複製手術矯正蹠足部畸形。該公司繼續拓展在足踝市場的影響力，引入其SpeedPlate快速壓縮植入物，一種創新的固定平台，在Lapiplasty和Adductoplasty手術以及足部其他常見骨骼融合手術中具有廣泛適用性。欲了解更多信息，請訪問 。
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
要了解有關Treace的更多信息，請在LinkedIn、X、Facebook和Instagram上關注我們。
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
聯繫人：
Treace Medical Concepts
馬克·L·黑爾
首席財務官
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
投資者:
吉爾馬丁集團
維維安·塞爾萬特斯
IR@treace.net
譯文內容由第三人軟體翻譯。
